logo
logo

Kriya Therapeutics Completes $100 Million Series B Financing To Advance Its Fully Integrated Platform For Designing, Developing And Manufacturing Transformative Gene Therapies

Kriya Therapeutics Completes $100 Million Series B Financing To Advance Its Fully Integrated Platform For Designing, Developing And Manufacturing Transformative Gene Therapies

07/14/21, 12:10 PM
Money raised
$100 million
Round Type
series b
Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, today announced the closing of a $100 Million Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.

Company Info

Company
Kriya Therapeutics
Additional Info
Our mission at Kriya Therapeutics is to expand the reach of gene therapy to address highly prevalent diseases affecting millions of patients.